Found: 30
Select item for more details and to access through your institution.
Principles of dose finding studies in cancer: a comparison of trial designs.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1107, doi. 10.1007/s00280-012-2059-8
- By:
- Publication type:
- Article
A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1115, doi. 10.1007/s00280-012-2062-0
- By:
- Publication type:
- Article
Pharmacokinetics and tissue distribution of larotaxel in rats: comparison of larotaxel-loaded microsphere with larotaxel-solution.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1131, doi. 10.1007/s00280-013-2104-2
- By:
- Publication type:
- Article
A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1141, doi. 10.1007/s00280-013-2106-0
- By:
- Publication type:
- Article
Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1147, doi. 10.1007/s00280-013-2107-z
- By:
- Publication type:
- Article
Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1159, doi. 10.1007/s00280-013-2108-y
- By:
- Publication type:
- Article
A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1173, doi. 10.1007/s00280-013-2109-x
- By:
- Publication type:
- Article
Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1183, doi. 10.1007/s00280-013-2112-2
- By:
- Publication type:
- Article
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1191, doi. 10.1007/s00280-013-2113-1
- By:
- Publication type:
- Article
Clinical implications of initial FDG-PET/CT in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1201, doi. 10.1007/s00280-013-2114-0
- By:
- Publication type:
- Article
A preclinical study on the protective effect of melatonin against methotrexate-induced small intestinal damage: effect mediated by attenuation of nitrosative stress, protein tyrosine nitration, and PARP activation.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1209, doi. 10.1007/s00280-013-2115-z
- By:
- Publication type:
- Article
Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1219, doi. 10.1007/s00280-013-2116-y
- By:
- Publication type:
- Article
Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1231, doi. 10.1007/s00280-013-2117-x
- By:
- Publication type:
- Article
Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1241, doi. 10.1007/s00280-013-2118-9
- By:
- Publication type:
- Article
A phase I pharmacokinetic study of PM00104 (Zalypsis((R))) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1247, doi. 10.1007/s00280-013-2119-8
- By:
- Publication type:
- Article
Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1255, doi. 10.1007/s00280-013-2120-2
- By:
- Publication type:
- Article
Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1265, doi. 10.1007/s00280-013-2122-0
- By:
- Publication type:
- Article
A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1273, doi. 10.1007/s00280-013-2126-9
- By:
- Publication type:
- Article
Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1287, doi. 10.1007/s00280-013-2127-8
- By:
- Publication type:
- Article
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1297, doi. 10.1007/s00280-013-2129-6
- By:
- Publication type:
- Article
Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1309, doi. 10.1007/s00280-013-2130-0
- By:
- Publication type:
- Article
Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1315, doi. 10.1007/s00280-013-2131-z
- By:
- Publication type:
- Article
Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1325, doi. 10.1007/s00280-013-2132-y
- By:
- Publication type:
- Article
Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1335, doi. 10.1007/s00280-013-2133-x
- By:
- Publication type:
- Article
Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1345, doi. 10.1007/s00280-013-2134-9
- By:
- Publication type:
- Article
The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1357, doi. 10.1007/s00280-013-2136-7
- By:
- Publication type:
- Article
A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1369, doi. 10.1007/s00280-013-2137-6
- By:
- Publication type:
- Article
Phase II randomized trial of carboplatin and gemcitabine with or without dexamethasone pre-treatment in patients with Stage IV non-small cell lung cancer.
- Published in:
- 2013
- By:
- Publication type:
- Report
Dodging a dogma: is treating beyond progression beneficial?
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1385, doi. 10.1007/s00280-013-2123-z
- By:
- Publication type:
- Article